Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

NCT06345287 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

133

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

RADIATION: radical radiotherapy (60Gy)
RADIATION: radical radiotherapy (66Gy)
RADIATION: radical radiotherapy (70Gy)
COMBINATION_PRODUCT: anti-PD-1 or PD-L1 antibody

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences